ArticleArthritis research & therapy2015
Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab.
Article in Arthritis research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.
- Pooled it
- Pooled it
- Plasma interferon-alpha is associated with double-positivity for autoantibodies but is not a predictor of remission in early rheumatoid arthritis-a spin-off study of the NORD-STAR randomized clinical trial.Arthritis research & therapy · 2021Trial
- Profiling type I and II interferon responses reveals distinct subgroups of pediatric patients with autoinflammatory disorders.The journal of allergy and clinical immunology. Global · 2025Article
- Insulin Sensitivity Controls Activity of Pathogenic CD4+ T Cells in Rheumatoid Arthritis.Cells · 2024Article
- Type I Interferons in Autoimmunity: Implications in Clinical Phenotypes and Treatment Response.The Journal of rheumatology · 2023Review
- CD317-Positive Immune Stromal Cells in Human "Mesenchymal Stem Cell" Populations.Frontiers in immunology · 2022Article
- Assessment of type I interferon signatures in undifferentiated inflammatory diseases: A Japanese multicenter experience.Frontiers in immunology · 2022Article
- Investigation of type I interferon responses in ANCA-associated vasculitis.Scientific reports · 2021Article
- Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis.Journal of personalized medicine · 2019Review
- An Easy and Reliable Strategy for Making Type I Interferon Signature Analysis Comparable among Research Centers.Diagnostics (Basel, Switzerland) · 2019Article
- Genetic and clinical markers for predicting treatment responsiveness in rheumatoid arthritis.Frontiers of medicine · 2019Review
- Rheumatoid arthritis-relevant DNA methylation changes identified in ACPA-positive asymptomatic individuals using methylome capture sequencing.Clinical epigenetics · 2019Article
- Dynamics of the Type I Interferon Response During Immunosuppressive Therapy in Rheumatoid Arthritis.Frontiers in immunology · 2019Article
- Regulating IRFs in IFN Driven Disease.Frontiers in immunology · 2019Review
- T-cell transcriptomics from peripheral blood highlights differences between polymyositis and dermatomyositis patients.Arthritis research & therapy · 2018Article
- The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy.The Journal of allergy and clinical immunology · 2018Article
- Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug Naïve Rheumatoid Arthritis.Frontiers in immunology · 2018Article
- IRF4 and IRGs Delineate Clinically Relevant Gene Expression Signatures in Systemic Lupus Erythematosus and Rheumatoid Arthritis.Frontiers in immunology · 2018Article
- Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy.Arthritis & rheumatology (Hoboken, N.J.) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionElevated type I interferon (IFN) response gene (IRG) expression has proven clinical relevance in predicting rituximab non-response in rheumatoid arthritis (RA). Interference between glucocorticoids (GCs) and type I IFN signaling has been demonstrated in vitro. Since GC use and dose are highly variable among patients before rituximab treatment, the aim of this study was to determine the effect of GC use on IRG expression in relation to rituximab response prediction in RA.
methodsIn two independent cohorts of 32 and 182 biologic-free RA patients and a third cohort of 40 rituximab-starting RA patients, peripheral blood expression of selected IRGs was determined by microarray or quantitative real-time polymerase chain reaction (qPCR), and an IFN-score was calculated. The baseline IFN-score was tested for its predictive value towards rituximab response in relation to GC use using receiver operating characteristics (ROC) analysis in the rituximab cohort. Patients with a decrease in disease activity score (∆DAS28) >1.2 after 6 months of rituximab were considered responders.
resultsWe consistently observed suppression of IFN-score in prednisone users (PREDN(+)) compared to non-users (PREDN(-)). In the rituximab cohort, analysis on PREDN(-) patients (n = 13) alone revealed improved prediction of rituximab non-response based on baseline IFN-score, with an area under the curve (AUC) of 0.975 compared to 0.848 in all patients (n = 40). Using a group-specific IFN-score cut-off for all patients and PREDN(-) patients alone, sensitivity increased from 41% to 88%, respectively, combined with 100% specificity.
conclusionsBecause of prednisone-related suppression of IFN-score, higher accuracy of rituximab response prediction was achieved in PREDN(-) patients. These results suggest that the IFN-score-based rituximab response prediction model could be improved upon implementation of prednisone use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.